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Commentary: 
 
 
What is already known on this topic 
 
Cognitive impairment is a reliable feature of major depressive disorder. Depressed 
individuals perform more poorly than never-depressed healthy volunteers across a range of 
neuropsychological tests. Cognitive impairments predict poor response to antidepressant 
drugs, persist after successful treatment [1] and are associated with poor psychosocial 
functioning.[2] Remediation of cognitive function in depression, for example by using 
cognitive training strategies [3] or cognitive-enhancing drugs such as modafinil,[4] have 
been shown to boost recovery from depression. The current study aimed to test whether 
standard antidepressant treatment improves cognitive function in depression. 
 
 
Methods of the study 
 
This was a longitudinal, randomised, open-label trial assessing the effects of three 
antidepressant drugs on cognitive function in depressed individuals. There were three 
treatment arms (one for each drug) as well as an untreated healthy control group. Cognitive 
performance in depressed patients was assessed at baseline and following 8 weeks of 
treatment; testing was completed in the control group at the same intervals. The raters who 
carried out clinical assessments were blind to treatment arm and cognitive performance 
throughout the trial. Enrolment of depressed individuals and healthy controls took place 
between 08 December 2008 and 30 September 2011 at 17 sites across the USA, New 
Zealand, South Africa, Australia and the Netherlands. Exclusion criteria for depressed 
individuals included a baseline score below 17 on the Hamilton Rating Scale for Depression 
(HRSD-17), a history of failure to respond or contraindications to any protocol drug or 
comorbidities that might interfere with the completion of assessments. A total of 1008 
depressed individuals and 336 never-depressed healthy controls were enrolled. Depressed 
participants, all of whom were unmedicated for at least the week preceding the start of the 
trial, were assigned to one of three oral antidepressants (escitalopram, sertraline or 
venlafaxine-XR) using a blocked randomisation procedure (with a block size of 12). At weeks 
0 (pre-treatment) and 8 (post-treatment), trained study personnel assessed depressive 
symptoms using the HRSD-17 and Quick Inventory of Depression Symptomatology (QIDS-
SR16); average baseline scores indicated a moderate-to-severe degree of symptoms. 
Cognitive function was measured using the computerised ‘IntegNeuro’ cognitive battery 
which comprised the following tests: attention (1-back continuous performance test); 
response inhibition (go-no go task); verbal memory (verbal interference task); executive 
function (Austin maze); cognitive flexibility (Stroop task); working memory (forward digit 
span); decision speed (choice reaction time); information processing (switching of attention 
between numbers and letters in a trails A and B task); and motor coordination (finger 
tapping). Scores of ≤7 on the HDRS-17 and ≤5 on the QIDS-SR16 at week 8 were used to 
define ‘remitter’ and ‘non-remitter’ groups. The analyses included 712 patients and 316 
controls who completed the study. 
 
 
What this paper adds 
 
 Owing to the large sample size, this study provides the clearest evidence to-date for the 
existence of cognitive impairment in depression and its resistance to treatment. 
 Baseline assessments confirmed significant cognitive impairment in depression on all tests 
(Cohen’s d effect sizes for healthy controls vs patients at week 0 ranged from 0.20 to 0.46) 
except for the forwards digit span (d=0.02). 
 Cognitive impairment in depressed individuals, relative to healthy volunteers, was not 
significantly affected by either antidepressant administration or treatment success, except 
for the executive function, which was the only test in which performance improved over 
the 8-week study period to a significantly greater extent in patients than controls. 
 There were no significant differences between the three treatment arms in post-
intervention cognitive functioning, suggesting that the protocol drugs were similarly 
ineffective, at the doses used, in treating cognitive impairment in depression. 
 
 
Limitations 
 
 A depressed group who were administered a placebo would have strengthened the 
design. In particular, this might have clarified the extent to which practice effects 
contributed to the apparent improvement on the Austin maze task (performance on which 
reflects a variety of cognitive processes) observed following antidepressant treatment; this 
finding conflicts with previous studies that used a placebo-controlled design.[5] 
 There was a low completion rate in the depressed group compared to the control group, 
71% (712/1008) and 94% (316/336), respectively, with no significant differences between 
treatment arms. Depressed participants that dropped out performed significantly worse 
on a test of attention at baseline than those who completed the study. This may have 
produced a bias in the analyses, which only included those who completed all 
assessments. This could be addressed by employing statistical techniques to correct for 
missing data, such as multiple imputation. 
 
 
What next in research 
 
 Large-scale trials assessing the ability of cognitive enhancing drugs or training techniques 
to augment existing treatments for depression will be necessary to test whether these 
strategies are effective, as suggested by preliminary work.[3,4] 
 The study of cognitive impairment in depression as an indicator of response-potential to 
different treatment modalities, including psychological therapies, may assist clinicians in 
better tailoring treatment plans to individual patients. 
 Trials assessing the effectiveness of other currently available antidepressants (and 
treatment modalities) at remediating cognitive impairment, as well as the development of 
novel treatment strategies specifically targeting cognitive impairment in depression, may 
be useful in helping to address this aspect of the condition. 
 
 
Do these results change your practices and why? 
 
No. As the trial drugs were similarly ineffective at improving cognitive impairment in 
depression at the doses used, these results are unlikely to cause an immediate change in 
standard treatment for depression. However, they may encourage health authorities to 
consider the importance of cognitive impairment in depression when formulating treatment 
guidelines. 
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